Press releases

Press releases

Inotrem’s COVID-19 Phase IIa Clinical Trial declared “National Priority Research” by the French government’s Clinical Trial Council

Paris, December 24. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government’

Read More »
Press releases

Inotrem announces Data Monitoring Committee (DMC) recommends continuation of Phase IIa study of nangibotide for the treatment of severe forms of COVID-19

Paris, December 21. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that an independent Data Monitoring Committee (DMC) recommends continuation of the Phase IIa study of nangibotide for the treatment of severe forms of COVID-19 hospitalized in intensive care units

Read More »
Press releases

First Patients Enrolled in the CoviTREM-1 Program

October 7, 2020 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, announces that it has enrolled its first patients. CoviTREM-1 is funded as part of the call for proposals PSPC-COVID, managed on behalf of the Government by Bpifrance as part of the “Investissements d’Avenir” Program

Read More »
Press releases

Inotrem expands its Leadership Team with the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and of Simon Lambden as Head of Medical Science

Paris, September 25 . 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and Simon Lambden as Head of Medical Science.

Read More »
Press releases

Inotrem expands Series B financing to €58 Million with a mix of Equity and Debt, adding new investors Fountain Healthcare Partners, Kreos and Bpifrance

Paris, February 11th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced a €5M capital increase financed by Fountain Healthcare Partners, a leading Irish venture capital firm with offices in Dublin and New

Read More »
Press releases

Inotrem was chosen to join the French Tech 120

January 20. 2020. Paris, France. Inotrem was chosen to join the French Tech 120. This program, launched by the President of the Republic and the Prime Minister in September 2019, is dedicated to support the development of fast growing startups. The French Tech Mission brings together some 50 French Tech

Read More »
Press releases

Inotrem secures strategic licensing agreement for a companion diagnostics test in septic shock.

January 21. 2020. Paris, France. Inotrem has entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1). This agreement consolidates existing ties between Roche Diagnostics and Inotrem who are jointly developing since 2017 an in vitro assay

Read More »
Press releases

Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock

Paris (France). November 21. 2019. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient

Read More »